progenity helps patients and their families prepare for life, with medically relevant health information starting before conception, through pregnancy, childhood, and adulthood. using our highly-complex molecular diagnostic testing, healthcare providers can access the most advanced genomic technology to guide patient care at critical life stages.
Company profile
Ticker
BIOR
Exchange
Website
CEO
Harry Stylli
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ASCENDANT MDX, INC., PROGENITY, INC.
SEC CIK
Corporate docs
Subsidiaries
Biora Therapeutics UK Limited ...
IRS number
273950390
BIOR stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
18 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
S-3
Shelf registration
8 Apr 24
8-K
Entry into a Material Definitive Agreement
2 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
Transcripts
BIOR
Earnings call transcript
2023 Q4
26 Mar 24
BIOR
Earnings call transcript
2023 Q3
13 Nov 23
BIOR
Earnings call transcript
2023 Q2
14 Aug 23
BIOR
Earnings call transcript
2023 Q1
15 May 23
BIOR
Earnings call transcript
2022 Q4
30 Mar 23
BIOR
Earnings call transcript
2022 Q3
14 Nov 22
BIOR
Earnings call transcript
2022 Q2
15 Aug 22
BIOR
Earnings call transcript
2022 Q1
11 May 22
BIOR
Earnings call transcript
2021 Q4
29 Mar 22
BIOR
Earnings call transcript
2021 Q4
28 Mar 22
Latest ownership filings
SC 13D/A
Athyrium Opportunities 2020 LP
2 Apr 24
4
Eric dEsparbes
15 Feb 24
4
CLARKE NEUMANN
15 Feb 24
4
ADITYA P. MOHANTY
15 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13D/A
Athyrium Opportunities 2020 LP
20 Dec 23
4
Jeffrey Ferrell
20 Dec 23
SC 13D/A
Athyrium Opportunities 2020 LP
19 Sep 23
4
Jeffrey Ferrell
19 Sep 23
4
CLARKE NEUMANN
17 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 12.57 mm | 12.57 mm | 12.57 mm | 12.57 mm | 12.57 mm | 12.57 mm |
Cash burn (monthly) | 4.63 mm | 2.04 mm | 24.48 mm | 10.21 mm | 3.68 mm | 3.81 mm |
Cash used (since last report) | 31.48 mm | 13.88 mm | 166.53 mm | 69.42 mm | 25.02 mm | 25.94 mm |
Cash remaining | -18.91 mm | -1.31 mm | -153.96 mm | -56.85 mm | -12.45 mm | -13.37 mm |
Runway (months of cash) | -4.1 | -0.6 | -6.3 | -5.6 | -3.4 | -3.5 |
Institutional ownership, Q3 2023
78.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 31 |
Opened positions | 29 |
Closed positions | 0 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 25.91 bn |
Total shares | 28.03 mm |
Total puts | 0.00 |
Total calls | 418.89 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Athyrium Opportunities 2020 | 12.35 mm | $25.81 mm |
Athyrium Capital Management | 10.93 mm | $23.72 bn |
CVI Investments | 3.75 mm | $0.00 |
Sabby Management | 376.56 k | $817.13 mm |
Vanguard | 278.75 k | $604.89 mm |
Geode Capital Management | 89.07 k | $193.35 mm |
BLK Blackrock | 65.05 k | $141.16 mm |
Schonfeld Strategic Advisors | 41.10 k | $89.19 mm |
Bridgeway Capital Management | 37.28 k | $80.90 mm |
STT State Street | 33.07 k | $71.77 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Dec 23 | Athyrium Opportunities III Co-Invest 1 | Warrant Common Stock | Grant | Acquire A | Yes | No | 5.5 | 5,039,236 | 27.72 mm | 5,039,236 |
18 Dec 23 | Athyrium Opportunities III Co-Invest 1 | Warrant Common Stock | Grant | Acquire A | Yes | No | 5 | 2,085,372 | 10.43 mm | 2,085,372 |
18 Sep 23 | Athyrium Opportunities III Co-Invest 1 | Common Stock | Grant | Acquire A | Yes | No | 0 | 9,235,281 | 0.00 | 10,929,763 |
18 Sep 23 | Athyrium Opportunities III Co-Invest 1 | Warrant Common Stock | Grant | Acquire A | Yes | No | 3.01 | 16,634,507 | 50.07 mm | 16,634,507 |
18 Sep 23 | Athyrium Opportunities III Co-Invest 1 | Warrant Common Stock | Grant | Acquire A | Yes | No | 0.001 | 7,399,226 | 7.40 k | 7,399,226 |
15 Aug 23 | Aditya P. Mohanty | Common Stock | Grant | Acquire A | No | No | 0 | 559,450 | 0.00 | 720,492 |
15 Aug 23 | Aditya P. Mohanty | Common Stock | Payment of exercise | Dispose F | No | No | 3.14 | 117,881 | 370.15 k | 161,042 |
15 Aug 23 | dEsparbes Eric | Common Stock | Grant | Acquire A | No | No | 0 | 219,650 | 0.00 | 278,662 |
15 Aug 23 | dEsparbes Eric | Common Stock | Payment of exercise | Dispose F | No | No | 3.14 | 40,022 | 125.67 k | 59,012 |
15 Aug 23 | Clarke Neumann | Common Stock | Grant | Acquire A | No | No | 0 | 210,175 | 0.00 | 262,193 |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
18 Apr 24
Biora Therapeutics Announces New Patent Covering Its BioJet Liquid Jet Delivery Technology
8 Apr 24
Biora Therapeutics Achieves Interim Results For Clinical Trial Of BT-600, Advancing NaviCap Platform Development
4 Apr 24
Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session
1 Apr 24
Earlier Biora Therapeutics Announced A $6M Registered Direct Offering Of 5,454,548 Shares Of Common Stock At A Price Of $1.10 Per Share
1 Apr 24
Press releases
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
8 Apr 24
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
4 Apr 24
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
3 Apr 24
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
1 Apr 24
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
26 Mar 24